

**Annual Report**  
**Division of Rheumatology**  
**Department of Medicine - Jewish General Hospital**  
**January 1 - December 31, 2016**

## **SUMMARY**

### **Introduction - Clinical**

Divisional members provide clinical services on Clinical Teaching Unit (CTU), out-patient clinic coverage, consult service as well as supervision of Internal Medicine residents and Rheumatology fellows as follows:

CTU: 2 weeks/year (Dr. Baron);

Consult service: 3 months/year (Dr. Baron, Dr. Berkson, Dr. Fallavollita, Dr. Gyger); Dr. Hudson: 1.5 months

Out-patient clinic: (Dr. Baron 7 half days per week; Dr. Berkson 6 half days per week; Dr. Fallavollita 6 half days per week; Dr. Gyger 7 half days per week)

Musculoskeletal ultrasound: (Dr. Fallavollita 1 day)

Video capillaroscopy: (Dr. Gyger ½ day)

In-Patient Follow up: (Dr. Hudson 3 hours per day)

Staff members strive for clinical innovation: use of anakinra for pericarditis (Dr. Berkson), multidisciplinary clinics (Dr. Baron).

### **1. Research and publications:**

An important study was published showing the longitudinal relationship of calcinosis in scleroderma to underlying ischemia (Baron M, Pope J, Robinson D, et al. Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. *Rheumatology (Oxford)* 2016;55:2148-55)

We published the last of a series of articles regarding oral abnormalities in scleroderma. This series will represent the definitive set of articles on this topic. (Baron M, Hudson M, Dagenais M, et al. Relationship between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results from a Canadian Oral Health Study. *Arthritis Care Res (Hoboken)* 2016;68:673-80.

Dr Hudson led a team of clinical researchers, geneticists and statisticians to identify the methylome signature of systemic autoimmune rheumatic diseases. The paper has just been published (*Epigenetics*. 2017 Apr 7:0. doi: 10.1080/15592294.2017.1303581).

Dr Hudson is supervising Dr Sabrina Hoa who is performing scleroderma fellowship.

Dr. Baron's primary research interest is scleroderma and focused on ways of measuring disease activity and damage in scleroderma, as well as on aspects of nutritional deficiencies caused by the disease.

Dr. Hudson pursues research in systemic autoimmune rheumatic diseases and translational

research aimed at studying the etiopathogenesis of systemic autoimmune rheumatic diseases (SARDs). Dr. Hudson is also the Director of the Canadian Inflammatory Myopathy Study (CIMS).

## **2. Teaching and learning (undergraduate and graduate):**

The division continues to participate in undergraduate and post-graduate medical education. Its members provide clinical supervision to medical students, residents and fellows regularly during their 2-week as attendings on the medical wards, full-day weekly general rheumatology clinics and consult service. They participate in the CaRMS Admission Committee for Internal Medicine (3 hours/year).

Dr. Berkson has developed a Rheumatoid Arthritis versus Osteoarthritis lecture, a didactic and interactive lecture for first year medical students. Every two years since 2013, she has presented a seminar series on osteoporosis for rheumatology fellows. In 2016 she was appointed chair of the Faculty of Medicine's Program Evaluation and Curriculum Outcomes Committee (Undergraduate).

### **Dr. M. Baron**

Formal Teaching: 2 hours

Clinical Teaching: 200 hours

Supervision: 50 hours Rheumatology fellows

Frequently with students and residents in outpatient clinic

### **Dr. L. Berkson**

Clinical Teaching: 2.4 weeks

Supervision: 2 hours Research trainee; ½ day/week residents in ambulatory care

Rheumatology Training Committee: 10 hrs/year

Program Evaluation and Curriculum Outcome Subcommittee: 2-2 ½ days per week

Osteoporosis Seminar x 3 for Rheumatology Fellows (6 hours)

Lecture for Med1 x 1

### **Dr. S. Fallavollita**

Undergraduate: 82 hours: 6 hrs MSK physical exam; 2 hrs Approach to arthritis; 2 hrs

Inflammatory back pain; 72 hrs TCP small group tutor

Postgraduate: 22 hours (15 hrs McGill Simulation Center; 4 hrs: PGY4 Academic Half Day MSK exam and Approach to rheumatoid arthritis; 2 hrs Rheumatology Half Day;

Supervision: 3 hrs/week 2 residents Continuity Clinic

JGH Site Director of Rheumatology Program: 2 hrs/month

Rheumatology Training Committee: 4 hrs/year

### **Dr. G. Gyger**

Capillaroscopy course: 24 hours: (Rheumatology week-end 12 hrs; IM Residents MSK week-end 12 hrs

Capillaroscopy course to rheumatologists: approximately around 25-30 hours per doctor

RAC course: 13 hours 45 min

Scleroderma introduction yearly: 1 hour

Resident teaching on a weekly basis

Clinical Teaching: 20% of time on clinical service supervising trainees

Supervision: Rheumatology fellow for publications on scleroderma and hematology fellow for case report

**Dr. M. Hudson**

Supervision: Research project: Mohamed Mansour, McGill Medical student; Teresa Semalulu, Northern Ontario School of Medicine, Formulation of evidence-based guidelines

Supervision and clinical teaching to Rhumatology and Internal Medicine fellows: 1 day/week general rheumatology and 6 weeks on consult service

Research Trainee supervision: 9 trainees

**3. Involvement in the community:**

Dr Baron holds the position of President of the Scleroderma Clinical Trials Consortium.

Dr Hudson co-leads a Scleroderma Clinical Trials Consortium working group on scleroderma renal crisis.

Dr Hudson was guest editor (with Dr Susanna Proudman) on a special issue on connective tissue diseases of Best Practice and Research: Clinical Rheumatology published in February 2016 (5-year IF 4.275).

Dr Hudson is medical advisor for Myositis Canada, a national grass-roots advocacy organization and AWISH, a local self-help group for patients with arthritis.

We have initiated our own vaccine clinic for our patients who are immunocompromised.

**4. Partnerships:**

Dr. Berkson is collaborating with Dr. Vartan Mardigyan (cardiology) in the treatment of patients with refractory pericarditis.

Dr Fallavollita is a member of a national organization developing a core clinical dataset for quality care for Rheumatoid Arthritis

Dr Gyger is part of an international consortium studying rare GI manifestations of scleroderma.

Dr Gyger is on a committee of the Scleroderma Clinical Trials Consortium seeking to establish training programs and a certification process for the use of video capillaroscopy in Scleroderma

The rheumatology research group has instituted the development of a new international research organization called The International Systemic Sclerosis Inception Cohort (InSync) with the aim of closely following the first few years of illness in patients with scleroderma from many different countries to develop a large enough cohort for important research. InSync includes researchers from Canada, United States, Germany, Holland, Sweden, Australia and Spain.

Dr. Baron is President of scleroderma clinical trials consortium, a worldwide body of scleroderma researchers.

Dr. Hudson participates in research on epigenetics of rheumatic diseases with a group at McGill University (CAN\_STAR) and has established a new national cohort in inflammatory myopathies (CIMS).

The Division runs an osteoporosis clinic in partnership with endocrinology. It has a once/month clinic for rheumatic disease with lung disease and/or pulmonary hypertension. Scleroderma patients are seen once per week for collection of data for the Canadian Scleroderma Research group.

**5. Milestones:**

There were no changes in staffing.

**6. Honours, awards, and prizes:**

Dr. Berkson is the inaugural chair of the Program Evaluation and Curriculum Outcome Committee for McGill University's Undergraduate Medical Education Program. She was honored as the Osler Fellow to the class of 2019.

Dr Hudson was the recipient of the Jeffry Shiroky prize (in recognition of her contribution to the field of inflammatory arthritis research), awarded at the Laurentienne Conference in Rheumatology held in Mont Tremblant, May 2016.

Dr Sabrina Hoa, a post-doctoral fellow under the supervision of Dr Hudson, was awarded The Arthritis Society's Post-doctoral fellowship award (2016-18), the CIHR Canada Graduate Scholarship award (2017-2019) and the Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program award (2017-2018).

**7. Fundraising:** None to report

**SECTION I - DIVISION STATUS UPDATE**

**1. Mission and objectives of the Division**

The Division strives to provide high level clinical care, education and research.

Our academic activities in terms of teaching require adequate time and space to teach in the outpatient setting. Any attempt to remove our offices and exam rooms from inside the hospital will seriously affect this. This would also likely affect our research as that also depends on seeing patients with adequate time and space to collect data.

**2. A nominative list of academic staff, their academic rank**

Murray Baron, MD: Professor of Medicine  
Marie Hudson, MD: Associate Professor with tenure  
Genevieve Gyger, MD: Assistant Professor  
Laeora Berkson, MD: Associate Professor of Medicine  
Sabrina Fallavollita, MD: Assistant Professor

## **SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF McGill**

### **1. Grants and awards received**

#### **Baron, Murray**

CIHR grant for pragmatic trial; established researcher -pharma roundtable re scleroderma; multiple publications

Scleroderma Society of Ontario

Canadian Scleroderma Research Group

Grouping of Canadian Companies and Corporations:

A multicenter, open label study to describe the safety of daily subcutaneous injections of Anakinar (r-metHuIL-1ra) in patients with rheumatoid arthritis.

University Of Michigan

A phase II study to evaluate subcutaneous abatacept vs placebo in diffuse cutaneous systemic sclerosis-a double-blind, placebo-controlled, randomized controlled trial (IM101-344)(ASSET)

Bayer (Canada) Inc.

A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc) (Study 16277)

Mount Sinai Hospital:

The Canadian ArTHritis CoHort (CATCH): A prospective cohort study of adults with new-onset inflammatory arthritis symptoms.

Hoffmann-La Roche Ltd, Canada :

A Phase II/III, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systematic sclerosis.

JSS Medical Research

A Canadian randomized controlled trial (RCT) of real world Cimzia treatment in RA: Randomizing to stop vs continued DMARDs.

Abbott Laboratories:

Real life evaluation of rheumatoid arthritis in Canadians taking HUMIRA.

#### **Hudson, Marie**

2016/10-2019/09 The Arthritis Society, Strategic Operating Grant

Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection against a Preventable Cause of Death in an at Risk Population?

Co-Principal Investigator with Ines Colmegna (nominated PI); Ward B, Bernatsky S, Piccirillo C \$359,906

2016/10-2019/09 The Arthritis Society, Strategic Operating Grant Randomized Controlled

Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Study  
Co-Investigator with Barlett SJ, Larche MJ, Baron M, Johnson SR, Fortin PR, Steele R, Pope J PI:  
Thombs BD  
\$359,686

2016/07-2019/07

Grant - Canadian Institutes of Health Research, Project  
Randomized Controlled Trial of an Internet-based Scleroderma Self- Management Program: A Scleroderma Patient-Centered Intervention Network (SPIN) Study  
Co-Investigator with Baron, Murray; Bartlett, Susan J; Boutron, Isabelle; Cuijpers, Pim; Fortin, Paul R; Gottesman, Karen; Johnson, Sindhu R; Kwakkenbos, Linda; Larche, Maggie J; Malcarne, Vanessa; Mayes, Maureen; Mouthon, Luc; Poiraudreau, Serge; Pope, Janet E; Riper, Heleen; Ruwaard, Jeroen; Sauve, Maureen; Schouffoer, Anne M; Steele, Russell J; Welling, Joep; Wigley, Fred  
PI: Thombs, Brett D  
\$561,909

2016/08-2019/07 Canadian Institutes of Health Research, Operating Grant: North America  
Re: Rare Pragmatic, multicentre, cluster, cohort randomised controlled treat-to- target trial for treatment of small intestinal bacterial overgrowth in systemic sclerosis  
Co-Investigator with Frech T; Greene T; Masetto A; Pimentel M; Szilagyi A  
PI: Murray Baron  
\$117,000

2016/07-2017/06 Canadian Institutes of Health Research, Project Grant (Bridge Funding)  
Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-Centered Intervention Network (SPIN) Study  
Co-Investigator with Baron, Murray; Bartlett, Susan J; Boutron, Isabelle; Cuijpers, Pim; Fortin, Paul R; Gottesman, Karen; Johnson, Sindhu R; Khanna, Dinesh; Kwakkenbos, Linda; Larche, Maggie J; Malcarne, Vanessa; Mayes, Maureen; Poole, Janet L; Pope, Janet E; Riper, Heleen; Ruwaard, Jeroen; Sauve, Maureen; Schouffoer, Anne M; Steele, Russell J; Van den Ende, Cornelia; Welling, Joep; Wigley, Fred  
Pis: Thombs, Brett D; Mouthon, Luc; Poiraudreau, Serge  
\$100,000

2016/07-2017/12 Department of the army- US Army Medical Research Acquisition Activity (USAMRAA)- DoD Peer Reviewed Medical Discovery Award Pollution, epigenetics and serologic markers of rheumatoid arthritis  
Co-Investigator with Ines Colmegna; Philip Awadalla; Marvin Fritzler; Audrey Smargiassi; Tomi Pastinen  
PI: Sasha Bernatsky  
\$244,838

2015/6 - 2018/1 Canadian Initiative for Outcomes in Rheumatology Care  
Preventing rheumatoid arthritis (Pre-RA): perspectives of people at risk and of rheumatologists on selected interventions  
Principal Investigator  
\$82,933

2012/1-2017/1 Canadian Institutes of Health Research (CIHR) Emerging Team: The Scleroderma Patient-centered Intervention Network  
Co-investigator; PI: Thombs, Brett  
\$1,499,765

2012/1- 2016/12 Canadian Institutes of Health Research (CIHR) - CCREES Epigenomic platform  
Multidimensional Epigenomics Mapping Centre (EMC) at McGill  
Co-Investigator with Bartha Knoppers; Guillaume Bourque; Gustavo Turecki; Ines Colmegna; Jacek Majewski; Jacques Drouin; Jacquetta Trasler; Mathieu Blanchette; Rob Sladek; Sasha Bernatsky; Yann Joly Principal Investigator: Mark Lathrop; Michael Meaney; Tomi Pastinen  
\$5,665,000

2015-2019 FRSQ Chercheur-clinicien Senior  
Recherches observationnelles portant sur les maladies systemiques autoimmunes rhumatismales  
Salary Award

Grouping of Canadian Companies and Corporations:  
The 1000 Canadian faces of lupus study.

Regroupement de compagnies, fondations et particuliers (Canada)  
Canadian inflammatory myopathy study group

Regroupement de particuliers  
LDI PI:  
Epigenetic signatures of systemic autoimmune rheumatic diseases - A Pilot Study

JSS Medical Research:  
Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).

### **Fallavollita, Sabrina**

JSS Medical Research:  
Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve Rheumatoid arthritis management: Canadian experience (Echo Study).

MUHC PI: Dr. Ines Colmegna:  
-liT Profile and functional implications of the production of age- associated inflammatory cytokines by hematopoietic progenitor cells in RA

Abbott Laboratories Ltd:  
Drug Canadian HUMIRA. Post Marketing Observational Epidemiological Study: Assessing Effectiveness in AS. Site contact and in charge of patient recruitment

### **Thombs, Brett**

Personal Support Awards

Arthritis Society Investigator Salary Award (\$350,000, 2013-2017).  
McGill University William Dawson Scholar Award (\$125,000, 2012-2017).

### Research Grants

#### CIHR

Project Scheme Grant. Randomized Controlled Trial of an Internet-based Scleroderma Self-Management Program: A Scleroderma Patient-Centered Intervention Network (SPIN) Study (\$569,909, 2016-2019)

Project Scheme Grant. Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-Centered Intervention Network (SPIN) Study (\$100,000, 2016-2017)

Knowledge Synthesis and Exchange Grant. Improving Depression Screening by Reducing Bias in Accuracy Estimates: An Independent Patient Data Meta-Analysis of the PHQ-9 (\$100,000, 2014-2015)

Emerging Team Grant: Rare Diseases. Emerging team: The Scleroderma Patient-centered Intervention Network (\$1,499,765 + \$205,000 partner funding, 2012-2017)

#### Arthritis Society

Strategic Operating Grant. Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Study (\$359,686, 2016-2019)

### Past Grants as Co-Investigator

Rare Disease Foundation. Microgrant Program. Illuminating the experience of caring for a patient with scleroderma through focus groups (PI Rice DB; \$3,467, 2016)

### Grouping of Individuals:

International Consortium for Behavioral/Educational/Psychological Interventions for Scleroderma. SPIN COHORT NETWORK (Director of project with over 40 sites from 8 countries and over 100 participating investigators)

## **2. Research Trainees Supervised**

### **Hudson, Marie**

#### **Undergraduate students**

Teresa Semalulu, MDCM 2018 (Northern Ontario School of Medicine). Formulating evidence-based guidelines for the rational use of cardiac echocardiography to screen for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) (funded by Canadian Rheumatology Association-Roche Summer Studentship). Abstract accepted for an oral presentation at the 4<sup>th</sup> Systemic Sclerosis World Congress, Lisbon, Portugal, February 2016

Charles Massie, MCDM 2016 (McGill), was funded by the Canadian Scleroderma Research Group STIHR grant. He completed a study looking at an association between anti-Ro antibodies



and prolonged QTc in SSc. He is first author on a manuscript published in Seminars in Arthritis Rheumatism (impact factor 4.1).

### **Postgraduate students**

Mohamed Mansour, McGill Medical student, supervised for a research project. He successfully applied and was awarded both a summer and winter research bursary. He presented a poster at the McGill Research Day. He will be presenting a poster at the Canadian Rheumatology Association annual meeting in Ottawa, in February 2017.

Teresa Semalulu, MDCM 2018 (Northern Ontario School of Medicine). Formulating evidence-based guidelines for the rational use of cardiac echocardiography to screen for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSe) (funded by Canadian Rheumatology Association-Roche Summer Studentship). Abstract accepted for an oral presentation at the 4th Systemic Sclerosis World Congress, fr Portugal, February 2016.

Koray Tascilar- post-doctoral fellow (2015-2016)

Research trainee supervision (MSc and PhD graduate students, postdoctoral fellows, medical students, residents). Thesis committees  
1-2 hrs per week per trainee

Published one first-authored manuscript (A and R, IF 9) and co-authored a paper in Nature Review Rheumatology (IF 10.5)

Sabrina Hoa- post-doctoral fellow (2015-2018)

Published 3 full length papers (Autoimmunity Reviews, IF 8.5; SAR, IF 4; and Medicine, IF 2), and one case report (A and R, IF 9); Awarded Arthritis Society's post-doctoral award (\$50,000 per year for 2 years)

Valerie Leclair- PGY5 (McGill)

Poster presentation at CRA February 2016; published 2 full-length manuscripts (PLOSone, IF 4; JSRD, no IF yet) and one case report (A and R, IF 9); first author on a book chapter (in press)  
Secured a position as post-doctoral fellow at the Karolinska Institute, Stockholm, Sweden (2016-2018)

Neha Srivastava- PGYS (McGill)

Poster presented CRA February 2016, full-length manuscript in preparation.

Yael Luck- PGY5 (McGill)

Co-authored a full-length manuscript (Medicine, IF 2)

Nicolas Richard- PGY5 (McGill)

Oral presentation at CRA February 2016- won best presentation in clinical research, full-length manuscript published (Rheumatology, IF 4)

Michael Wodkowski- PGY4 (McGill)

Poster to be presented at CRA February 2017, full-length manuscript in preparation

Teresa Cafaro- PGY3 (McGill)

Poster to be presented at CRA February 2017, full-length manuscript in preparation

Mayank Jha- PGY2 (McGill)

Poster to be presented at CRA February 2017, full-length manuscript in preparation

## **2. Scholarly works published in the 2016 calendar year**

--Baron M, Pope J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larche M, Abu-Hakima M, Rodriguez-Reyna TS, Cabral-Castaneda AR, Fritzler MJ, Wang M, Hudson M. Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. *Rheumatology (Oxford, England)* 2016;55:2148-55

--Wu M, Assassi S, Salazar GA, Pedroza C, Gorlova OY, Chen WV, Charles J, Taing ML, Liao K, Wigley FM, Hummers LK, Shah AA, Hinchcliff M, Khanna D, Schioppa E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Zhou X, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Fritzler MJ, Molitor JA, Segal BM, Movahedian M, Martin J, Varga J, Mayes MD. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. *Arthritis research & therapy* 2016;18:20

--Riehm KE, Kwakkenbos L, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poiraudau S, Nielsen K, Baron M, Frech T, Hudson M, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, Thombs BD. Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. *Arthritis care & research* 2016;68:1195-200

--Baron M, Hudson M, Dagenais M, Macdonald D, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Fritzler M, Wang M, Gornitsky M. Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. *Arthritis care & research* 2016;68:673-80

--Baron M. Targeted Therapy in Systemic Sclerosis. *Rambam Maimonides medical journal* 2016;7(4): e0030 doi: 10.5041/RMMJ.10257

--Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schioppa E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. *Arthritis & rheumatology (Hoboken, NJ)* 2016;68:299-311

--Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet (London, England)* 2016

--Morardet L, Avouac J, Sammour M, Baron M, Kahan A, Feydy A, Allanore Y. Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro-Osteolysis in Systemic Sclerosis. *Arthritis care & research* 2016;68:366-73

--Nevskaya T, Baron M, Pope JE. European scleroderma study group activity index captures variations in disease activity over time and predicts organ damage in early systemic sclerosis: Data from the Canadian scleroderma research group. *Annals of the Rheumatic Diseases* 2016;75:65-6

--Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirjak L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Muller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. *Annals of the rheumatic diseases* 2016

--Valenzuela A, Baron M, Herrick AL, Proudman S, Stevens W, Rodriguez-Reyna TS, -Vacca A, Medsger TA, Jr., Hinchcliff M, Hsu V, Wu JY, Fiorentino D, Chung L. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. *Seminars in arthritis and rheumatism* 2016

--Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M. Measures of disease status in systemic sclerosis: A systematic review. *Seminars in arthritis and rheumatism* 2016

--Richard N, Hudson M, Gyger G, Baron M, Sutton E, Khalidi N, Pope JE, Carrier N, Larche M, Albert A, Fortin PR, Thorne C, Masetto A. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. *Rheumatology (Oxford, England)* 2016

--Levis B, Kwakkenbos L, Hudson M, Baron M, Thombs BD. The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. *Clinical rheumatology* 2016

--Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. *Seminars in arthritis and rheumatism* 2016

--Hoa S, Leclair V, Hudson M. Cutaneous lymphangiectasia in association with systemic sclerosis. *Arthritis & rheumatology (Hoboken, NJ)* 2016

--Hudson M, Luck Y, Stephenson M, Choi MY, Wang M, Baron M, Fritzler MJ. Anti-HMGCR antibodies in systemic sclerosis. *Medicine* 2016;95:e5280

--Tascilar K, Dell'Aniello S, Hudson M, Suissa S. Statins and Risk of Rheumatoid Arthritis: A Nested Case-Control Study. *Arthritis & rheumatology (Hoboken, NJ)* 2016;68:2603-11

--Hudson M, \*Tascilar K, Suissa S. Comparative effectiveness research with administrative health data in rheumatoid arthritis. *Nat Rev Rheumatol* 2016 ar 24;374(12):1145-54

--Delisle VC, Gumuchian ST, Pelaez S, Malcarne VL, El-Baalbaki G, Korner A, Hudson M, Baron M, Thombs BD. Reasons for non-participation in scleroderma support groups. *Clinical and experimental rheumatology* 2016;34 Suppl 100:56-62

--Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. *Medicine* 2016;95:e4713

--Leclair V, Regardt M, Wojcik S, Hudson M. Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. *PloS one* 2016;11:e0160753

--Proudman S, Nikpour M, Hudson M. Improving care of autoimmune connective tissue diseases: Lessons from longitudinal cohorts. *Best practice & research Clinical rheumatology* 2016;30:1-2

--Harel D, Hudson M, Iliescu A, Baron M, Steele R. Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. *The Journal of rheumatology* 2016;43:1510-8

--McGregor K, Bernatsky S, Colmegna I, Hudson M, Pastinen T, Labbe A, Greenwood CM. An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies. *Genome biology* 2016;17:84

--Thombs BD, Hudson M. No Evidence for Depression Screening in Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. *The Journal of rheumatology* 2016;43:992

--Hudson M, Tascilar K, Suissa S. Comparative effectiveness research with administrative health data in rheumatoid arthritis. *Nature reviews Rheumatology* 2016;12:358-66

--Gumuchian ST, Pelaez S, Delisle VC, Carrier ME, Jewett LR, El-Baalbaki G, Fortune C, Hudson M, Impens A, Korner A, Persmann J, Kwakkenbos L, Bartlett SJ, Thombs BD. Exploring Sources of Emotional Distress among People Living with Scleroderma: A Focus Group Study. *PloS one* 2016;11:e0152419

--Racine M, Hudson M, Baron M, Nielson WR. The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. *Journal of pain and symptom management* 2016;52:43-53

--Bernatsky S, Smargiassi A, Barnabe C, Svenson LW, Brand A, Martin RV, Hudson M, Clarke AE, Fortin PR, van Donkelaar A, Edworthy S, Belisle P, Joseph L. Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. *Environmental research* 2016;146:85-91

--Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Korner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD. Development and Validation of the Body Concealment Scale for Scleroderma. *Arthritis care & research* 2016;68:1158-65

--Levis B, Rice DB, Kwakkenbos L, Steele RJ, Hagedoorn M, Hudson M, Baron M, Thombs BD.

Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. *Arthritis care & research* 2016;68:1143-9

--Pope JE, Rothfield NF, Ramsey-Goldman R, Douglas Smith C, Bernatsky SR, Furie RA, Hudson M, Burgos-Vargas R, Senecal JL, Inanc M, van Vollenhoven RF, Chandran V, Nash PT, Muangchan C. Reply. *Arthritis care & research* 2016;68:1053-4

--Oros Klein K, Grinek S, Bernatsky S, Bouchard L, Ciampi A, Colmegna I, Fortin JP, Gao L, Hivert MF, Hudson M, Kobor MS, Labbe A, MacIsaac JL, Meaney MJ, Morin AM, O'Donnell KJ, Pastinen T, Van Ijzendoorn MH, Voisin G, Greenwood CM. funtooNorm: an R package for normalization of DNA methylation data when there are multiple cell or tissue types. *Bioinformatics (Oxford, England)* 2016;32:593-5

### **3. Grant reviews**

Hudson, Dr. Marie

FRQS Comité d'évaluation des demandes de bourses chercheurs-cliniciens J2-Senior - 2016

Submitted by:

Murray Baron, MD

Chief, Division of Rheumatology, JGH